Search results
How to Safely Discontinue Multiple Myeloma Maintenance Care
Medscape· 4 days agoNew research suggested that the key to safely discontinuing multiple myeloma maintenance therapy is...
CARsgen’s CAR T MM therapy shows early signs of efficacy in Phase I trial
Clinical Trials Arena via Yahoo Finance· 9 hours agoShanghai based-biotech company CARsgen Therapeutics has announced that its CAR T cell candidate...
Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma
MedPage Today· 4 days agoMedPage Today brought together three expert leaders in the field: Moderator...
2024 Warren Alpert Foundation Prize Honors Four Pi | Newswise
Newswise· 7 days agoThe 2024 Warren Alpert Foundation Prize has been awarded to four scientists whose transformational discoveries led to the creation of chimeric antigen receptor (CAR) T cells, a treatment that ...
Head to Head Survey: Evaxion Biotech A/S (NASDAQ:EVAX) and Halozyme Therapeutics (NASDAQ:HALO)
ETF DAILY NEWS· 4 days agoHalozyme Therapeutics (NASDAQ:HALO – Get Free Report) and Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the ...
Legend Biotech (NASDAQ:LEGN) Shares Gap Up to $42.45
ETF DAILY NEWS· 10 hours agoLegend Biotech Co. (NASDAQ:LEGN – Get Free Report) shares gapped up prior to trading on Monday . Legend Biotech shares last traded at $42.20, with a volume of 37,307 shares changing hands. Scotiabank ...
Entrada Therapeutics (NASDAQ:TRDA) versus BioLineRx (NASDAQ:BLRX) Head to Head Comparison
ETF DAILY NEWS· 3 days agoBioLineRx (NASDAQ:BLRX – Get Free Report) and Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast ...
BioLineRx Ltd. to Post Q2 2024 Earnings of ($0.01) Per Share, Zacks Small Cap Forecasts...
ETF DAILY NEWS· 5 days agoBioLineRx Ltd. (NASDAQ:BLRX – Free Report) – Analysts at Zacks Small Cap issued their Q2 2024 earnings per share (EPS) estimates for BioLineRx in a research note issued on Monday, June 10th.
Short Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Increases By 16.9%
ETF DAILY NEWS· 2 days agoC4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) was the recipient of a significant increase in short interest in May. As of May 31st, there was short interest totalling 13,260,000 shares ...
Oppenheimer Lowers Cellectis (NASDAQ:CLLS) Price Target to $10.00
ETF DAILY NEWS· 4 days agoCellectis (NASDAQ:CLLS – Get Free Report) had its target price dropped by Oppenheimer from $11.00 to $10.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage presently ...
